EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

“Within‐Trial” Prognostic Score Adjustment Is Targeted Maximum Likelihood Estimation

Emilie Højbjerre-Frandsen iD, Alejandro Schuler

Pharmaceutical Statistics · 2026

DOI: 10.1002/pst.70080 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceutical Statistics, 2026. Verfasst von Emilie Højbjerre-Frandsen und 1 weiteren Autor:innen. Beteiligte Einrichtung: Biostatistics Methods, Novo Nordisk A/S, Søborg, Denmark. Hauptthemen laut MEDLINE: Randomized Controlled Trials as Topic, Research Design. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Innovationsfonden.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Adjustment for “super” or “prognostic” composite covariates has become more popular in randomized trials recently. These prognostic covariates are often constructed from historical data obtained from previous clinical trials or registries by fitting a predictive model of the outcome on the raw covariates. A natural question that we have been asked by applied researchers is whether this can be done without the historical data: can the prognostic covariate be constructed or derived from the trial data itself, possibly using different folds of the data, before adjusting for it? Here we clarify that such “within‐trial” prognostic adjustment is nothing more than a form of targeted maximum likelihood estimation (TMLE), a well‐studied procedure that typically improves the power of trial analyses. We therefore argue that there is no reason to reinvent the wheel: within‐trial prognostic score adjustment should be referred to as TMLE, without qualification.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Randomized Controlled Trials as TopicResearch DesignHumansLikelihood FunctionsPrognosisModels, Statistical

Stichwörter der Autor:innen

causal inferenceprognostic scoresrandomized trialstargeted learning

Autor:innen und Institutionen

  • Biostatistics Methods, Novo Nordisk A/S, Søborg, Denmark.
  • Department of Mathematical Sciences, Aalborg University, Aalborg Øst, Denmark.
  • Division of Biostatistics, University of California Berkeley, Berkeley, California, USA.

ORCID-Profile: Emilie Højbjerre-Frandsen

Förderung

  • Innovationsfonden

Zitieren

APA

Højbjerre-Frandsen, E., & Schuler, A. (2026). “Within‐Trial” Prognostic Score Adjustment Is Targeted Maximum Likelihood Estimation. Pharmaceutical Statistics. https://doi.org/10.1002/pst.70080

Vancouver

Højbjerre-Frandsen E, Schuler A. “Within‐Trial” Prognostic Score Adjustment Is Targeted Maximum Likelihood Estimation. Pharmaceutical Statistics. 2026. doi:10.1002/pst.70080

BibTeX
@article{HjbjerreFrandsen2026,
  author = {Højbjerre-Frandsen, Emilie and Schuler, Alejandro},
  title = {“Within‐Trial” Prognostic Score Adjustment Is Targeted Maximum Likelihood Estimation},
  journal = {Pharmaceutical Statistics},
  year = {2026},
  doi = {10.1002/pst.70080}
}
Kostenlos starten →